Press releases
2024-04-25 13:10
Lipum announces final outcome of the rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
2024-04-23 18:40
Lipum announces preliminary outcome of the rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
Lipum AB (Publ), a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases...
2024-04-12 16:00
Lipum has been granted funding from Swelife
Lipum (publ) announce today that the project “Identifying proteomic biomarkers to predict the course of early RA” has been granted 2,8 MSEK...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
2024-04-03 12:45
Lipum publishes prospectus regarding the rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
2024-04-02 13:25
Lipum AB - Report from the Extraordinary General Meeting
An Extraordinay General Meeting (the “EGM”) in Lipum AB (publ), corporate identity number 556813-5999 (“Lipum” or the “Company”)...
2024-04-02 08:30
Lipum strengthens its protection of the drug candidate SOL-116 through a patent application for inflammation-driven cancer
Lipum has developed the drug candidate SOL-116 with the aim of treating inflammatory diseases in a new way. This is based on the discovery of a unique...
2024-03-20 16:57
Statement from the Board of Directors of Lipum regarding the mandatory public offer from Flerie Invest AB
The Board of Directors of Lipum AB (publ) (“Lipum” or the “Company”) unanimously recommends the shareholders of Lipum not to accept...
2024-03-19 08:30
LIPUM REPORTS FIRST PATIENT INCLUDED IN THE ONGOING PHASE I CLINICAL STUDY WITH SOL-116
Lipum announces that the first patient with rheumatoid arthritis (RA) has been enrolled and dosed with SOL-116 or placebo in the ongoing phase I clinical...